A federal judge has now ruled that the challenged patent is valid but went on the allow Apotex to distribute what generic it has already put in the wholesale channel. Apotex will appeal the patent judgment. Bristol Myers expects a big cut in its profits this year as prices for the drug have been sharply cut.
More to come.